Having trouble viewing this email? View in your browser.
ESCMID Logo

11 February 2020
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

ECCMID 2020 is approaching: don’t miss the opportunity to enjoy Prof. Brigitte Autran’s Keynote Lecture. Register now!

We are extremely pleased to have Prof. Autran (Emeritus Professor of Immunology at Sorbonne-Université Faculty of Medicine) as a keynote speaker at ECCMID 2020! The title of her lecture will be “Immune control of HIV infection”.

Visit the ECCMID 2020 website to find out about our outstanding keynote speakers!

› Read more

19th ESCMID Summer School – Registrations now open

Registrations are now open for the 19th ESCMID Summer School, to be held in Carcavelos, Portugal from 27 June – 4 July 2020.

Visit the course website to view the programme, as well as other information about the course. Be quick, this course is bound to sell out soon!

 

› Read more

EITaF Mailing list: Subscribe to receive outbreak news in your inbox!

Did you know that you can now receive email alerts every time that a new piece of EITaF Outbreak News is published – EITaF is the official ESCMID source for news about the coronavirus outbreak.

If you log in to your ESCMID account using your ESCMID login credentials and choose the link ‘Newsletter and Mailing List’ in the right-hand column, You can opt-in to receiving EITaF news alerts.

› Read more
 

Course announcement: Colistin and other last-line anibiotics against XDR/PDR Gram-negatives – Antwerp, Belgium

Don’t miss the upcoming ESCMID Postgraduate Education course ‘Colistin and other last-line anibiotics against XDR/PDR Gram-negatives’ to be held in Antwerp, Belgium from 1-3 July 2020.

Find out about this and other upcoming ESCMID Educational Courses and Workshops on the ESCMID courses website.

› Read more
 

ECCMID 2020 Programme Book Grants 2020

Did you know that all money collected from the sale of ECCMID 2020 printed programme books (€20 each during registration) is contributed to supporting abstract authors from low-income countries to attend ECCMID.

Read about the 6 current grantees on the new-look ECCMID Website. More grants will be made available as the remaining programme books are sold.

› Read more
 

Open call to join the CMI editorial team

Clinical Microbiology and Infection (CMI) is looking for an editor in clinical microbiology to join the editorial team. They are looking for an editor who will deal mainly with studies done in the laboratory, whether the routine clinical laboratory or a research one. CMI aims to aid the readers in using research evidence for the benefit of patients. Improving the methods and the reporting of results is a worthy goal, and you can contribute by being an editor. The call is open until March 31st 2020. Read more about the call and how to apply for this opportunity here.

› Read more
 

CMI highlight: Semi-mechanistic PK-PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii

Acinetobacter baumannii is one of the most difficult to treat multi-drug resistant (MDR) pathogens responsible for opportunistic nosocomial infections worldwide. It can cause a wide range of infections and has the ability to become resistant to broad range of drugs. In face of these resistances, interest in using neglected and disused antibiotics like polymyxins (colistin and polymyxin B (PMB)) has surged, especially in combination with other antibiotics like the carbapenem minocycline (MIN), as the last line of defence against MDR A. baumannii. V. Aranzana-Climent et al. develop a semi-mechanistic PK/PD model to gain insights on the qualitative and quantitative determinants of the interaction between PMB and MIN.

The authors’ model shows that the combination of PMB and MIN could work at clinically achievable concentrations of both antibiotics. Notably, the simulations essentially show the asymmetric nature of the interaction, where MIN is driving the effect and PMB is helping, suggesting that MIN should be used at relatively high dose whereas PMB could be used at relatively low dose. This synergy was observed also in PMB resistant A. baumannii. The authors also conclude that further study of protein binding of MIN in humans is necessary before any definitive recommendation can be issued.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.